Home/ImmunoMet Therapeutics/Paul Lammers, M.D., M.Sc.

PL

Paul Lammers, M.D., M.Sc.

Executive Chairman of the Board

ImmunoMet Therapeutics

Therapeutic Areas

Oncology Fibrosis

ImmunoMet Therapeutics Pipeline

Drug	Indication	Phase
Lixumistat (IM156)	Pancreatic Cancer	Phase 1b

Leadership Team at ImmunoMet Therapeutics

Dean J. Welsch, PhD

Interim Chief Executive Officer / Chief Scientific Officer

View full ImmunoMet Therapeutics profile